Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

September 17, 2007

Primary Completion Date

June 3, 2013

Study Completion Date

May 18, 2017

Conditions
HIV Infections
Interventions
DRUG

Raltegravir poloxamer film coated tablet

Final Selected Dose: 400-mg tablet taken orally twice daily.

DRUG

Raltegravir chewable tablet

Final Selected Dose: Weight based dose of \~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily.

DRUG

Raltegravir oral granules for suspension (20 mg/mL)

Weight based dose of \~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data.

DRUG

Raltegravir poloxamer film coated tablet

Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants \< 25 kg were switched to a weight-based dose of the chewable tablet.

Trial Locations (42)

1862

Soweto IMPAACT CRS, Johannesburg

2001

Shandukani Research CRS, Johannesburg

4001

Durban Paediatric HIV CRS, Durban

7505

Family Clinical Research Unit (FAM-CRU) CRS, Tygerberg

10016

Nyu Ny Nichd Crs, New York

10029

Metropolitan Hosp. NICHD CRS, New York

10032

Columbia IMPAACT CRS, New York

10457

Bronx-Lebanon Hospital Center NICHD CRS, The Bronx

10461

Jacobi Med. Ctr. Bronx NICHD CRS, The Bronx

19104

Philadelphia IMPAACT Unit CRS, Philadelphia

20010

Children's National Med. Ctr. Washington DC NICHD CRS, Washington D.C.

20060

Howard Univ. Washington DC NICHD CRS, Washington D.C.

21287

Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore

27710

DUMC Ped. CRS, Durham

32209

Univ. of Florida Jacksonville NICHD CRS, Jacksonville

33316

South Florida CDTC Ft Lauderdale NICHD CRS, Fort Lauderdale

33606

USF - Tampa NICHD CRS, Tampa

60612

Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago

70112

Tulane Univ. New Orleans NICHD CRS, New Orleans

80045

Univ. of Colorado Denver NICHD CRS, Aurora

91803

Usc La Nichd Crs, Alhambra

94143

Univ. of California San Francisco NICHD CRS, San Francisco

98105

Seattle Children's Research Institute CRS, Seattle

92093-0672

University of California, UC San Diego CRS, La Jolla

90027-6062

Children's Hospital of Los Angeles NICHD CRS, Los Angeles

90095-1752

David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles

60614-3393

Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS, Chicago

02115

Children's Hosp. of Boston NICHD CRS, Boston

02118

Boston Medical Center Ped. HIV Program NICHD CRS, Boston

01605

WNE Maternal Pediatric Adolescent AIDS CRS, Worcester

11794-8111

SUNY Stony Brook NICHD CRS, Stony Brook

38105-3678

St. Jude Children's Research Hospital CRS, Memphis

77030-2399

Texas Children's Hospital CRS, Houston

C1221ADC

Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires

Unknown

Gaborone CRS, Gaborone

30.130-100

SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte

91350-200

Hospital Nossa Senhora da Conceicao NICHD CRS, Porto Alegre

20221-903

Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro

21941-612

Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro

01246-900

Inst de Infectologia Emilio Ribas Sao Paulo Brazil NICHD CRS, São Paulo

14049-900

Univ. of Sao Paulo Brazil NICHD CRS, São Paulo

00936

San Juan City Hosp. PR NICHD CRS, San Juan

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00485264 - Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents | Biotech Hunter | Biotech Hunter